ENGINEERINGNET.EU – ThromboGenics, a biotech player based in Belgium, will use the funds mainly for further growth purposes.
Dr Patrik De Haes, CEO of ThromboGenics said: “The additional funds will allow us to build a first-class U.S. commercial organization ahead of the anticipated launch of ocriplasmin.”
“The potential of ocriplasmin to provide a new treatment paradigm for patients with symptomatic VMA including macular hole has been validated by our recent agreement with Alcon, giving it the commercial rights to this innovative product outside the U.S.”
“The proceeds should also enable us to become a profitable, ophthalmology company that both creates value for our shareholders and brings drugs with significant benefits to patients.”
(picture: Thrombogenics)
BACKGROUNDER
ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company’s lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA).
